Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop

Affiliations

¹ Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK. Electronic address: paul.lorigan@christie.nhs.uk.
² Department of Medical Oncology, Gustave Roussy, Villejuif, France.

Free article

Editorial

P Lorigan et al. Ann Oncol. 2019.

Free article

. 2019 Jul 1;30(7):1038-1040.

doi: 10.1093/annonc/mdz182.

¹ Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK. Electronic address: paul.lorigan@christie.nhs.uk.
² Department of Medical Oncology, Gustave Roussy, Villejuif, France.

No abstract available

Comment on

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B. Jansen YJL, et al. Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110. Ann Oncol. 2019. PMID: 30923820